These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27041244)

  • 1. Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study.
    Chantzichristos VG; Agouridis AP; Moutzouri E; Stellos K; Elisaf MS; Tselepis AD
    Curr Vasc Pharmacol; 2016; 14(5):474-480. PubMed ID: 27041244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34(+) progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia.
    Chantzichristos VG; Agouridis AP; Moutzouri E; Stellos K; Elisaf MS; Tselepis AD
    Atherosclerosis; 2016 Aug; 251():240-247. PubMed ID: 27415612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
    Kim CH; Han KA; Yu J; Lee SH; Jeon HK; Kim SH; Kim SY; Han KH; Won K; Kim DB; Lee KJ; Min K; Byun DW; Lim SW; Ahn CW; Kim S; Hong YJ; Sung J; Hur SH; Hong SJ; Lim HS; Park IB; Kim IJ; Lee H; Kim HS
    Clin Ther; 2018 Jan; 40(1):83-94. PubMed ID: 29223557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
    Makariou SE; Liberopoulos EN; Agouridis AP; Challa A; Elisaf M
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):382-6. PubMed ID: 22431864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia.
    Mindrescu C; Gupta RP; Hermance EV; DeVoe MC; Soma VR; Coppola JT; Staniloae CS
    Vasc Health Risk Manag; 2008; 4(6):1439-47. PubMed ID: 19337557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
    Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
    Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
    Kei A; Tellis C; Liberopoulos E; Tselepis A; Elisaf M
    Cardiovasc Ther; 2014 Aug; 32(4):139-46. PubMed ID: 24618208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
    Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
    Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia.
    Nozue T; Michishita I
    Lipids Health Dis; 2015 Jul; 14():67. PubMed ID: 26149129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes.
    Poreba M; Mostowik M; Siniarski A; Golebiowska-Wiatrak R; Malinowski KP; Haberka M; Konduracka E; Nessler J; Undas A; Gajos G
    Cardiovasc Diabetol; 2017 Apr; 16(1):50. PubMed ID: 28410617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
    Alfaddagh A; Elajami TK; Ashfaque H; Saleh M; Bistrian BR; Welty FK
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29246960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
    Agouridis AP; Kostapanos MS; Tsimihodimos V; Kostara C; Mikhailidis DP; Bairaktari ET; Tselepis AD; Elisaf MS
    Int J Clin Pract; 2012 Sep; 66(9):843-53. PubMed ID: 22897461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients.
    Betto M; Fares J; Saliba N; Ballout H
    Ann Saudi Med; 2017; 37(5):366-374. PubMed ID: 28988251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding Alirocumab to Rosuvastatin Helps Reduce the Vulnerability of Thin-Cap Fibroatheroma: An ALTAIR Trial Report.
    Sugizaki Y; Otake H; Kawamori H; Toba T; Nagano Y; Tsukiyama Y; Yanaka KI; Yamamoto H; Nagasawa A; Onishi H; Takeshige R; Nakano S; Matsuoka Y; Tanimura K; Takahashi Y; Fukuyama Y; Shinke T; Ishida T; Hirata KI
    JACC Cardiovasc Imaging; 2020 Jun; 13(6):1452-1454. PubMed ID: 32199850
    [No Abstract]   [Full Text] [Related]  

  • 15. Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study.
    Solberg OG; Stavem K; Ragnarsson A; Beitnes JO; Skårdal R; Seljeflot I; Ueland T; Aukrust P; Gullestad L; Aaberge L
    Catheter Cardiovasc Interv; 2019 Nov; 94(5):660-668. PubMed ID: 30790446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
    Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database.
    Karlson BW; Palmer MK; Nicholls SJ; Barter PJ; Lundman P
    Atherosclerosis; 2017 Oct; 265():54-59. PubMed ID: 28863328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension.
    Mitsiou E; Boutari C; Kotsis V; Georgianou E; Doumas M; Karagiannis A; Athyros VG
    Curr Vasc Pharmacol; 2018; 16(4):393-400. PubMed ID: 28669329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
    Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.